Gossamer Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters? Option to Purchase Additional Shares

SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc.?(Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the closing of its previously announced initial public offering of 19,837,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,587,500 additional shares, at a price to th